Tande­mAI rais­es $35M in Se­ries A for small mol­e­cule dis­cov­ery, wet labs

Tande­mAI, a small mol­e­cule- and pre­clin­i­cal-fo­cused tech­nol­o­gy com­pa­ny, raised $35 mil­lion in a Se­ries A round of fi­nanc­ing a lit­tle over a year af­ter rais­ing an ini­tial $25 mil­lion to get start­ed.

CEO Jeff He says the com­pa­ny of­fers a three-in-one ap­proach for biotech and phar­ma com­pa­nies: a drug dis­cov­ery plat­form of small mol­e­cules, Chi­na-based wet labs, and ex­perts across var­i­ous fields in­clud­ing chem­istry and AI, all of whom work with clients to bring a drug can­di­date out of the pre­clin­i­cal stage.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.